We use analytics and advertising cookies, which you can accept or reject; see our privacy policy.

Current choice:

Thrombin

Thrombin inhibitors block the serine protease that converts fibrinogen into fibrin at the end of coagulation. Thrombin also activates platelets and other cells through protease-activated receptors (PARs). The receptor cloned in 1991 showed that thrombin cleaves the receptor N-terminus and unmasks a tethered ligand. Direct inhibitors bind the active site and are used in coagulation, platelet and vascular research. Dabigatran came from a structure-based design program reported in 2002, and dabigatran etexilate is its orally available prodrug. Argatroban, bivalirudin, inogatran and ximelagatran are further direct thrombin inhibitors. Atopaxar hydrobromide acts on the receptor side as a PAR-1 antagonist, whereas RWJ-445167 inhibits both thrombin and factor Xa.

1 Item

  • TRAP-14
    Cat. No.
    A77888
    CAS No.
    137339-65-2

    TRAP-14

    Synonyms: SFLLRNPNDKYEPF

    TRAP-14 (SFLLRNPNDKYEPF) is a synthetic peptide that acts as an agonist for the thrombin receptor. This compound is utilized in research to study thrombin signaling pathways and their implications in various physiological and pathological processes. Its ability to activate the thrombin receptor makes it valuable for investigating thrombosis, inflammation, and cardiovascular diseases.

    In stock View Details
    1 mg
    $55.00
    5 mg
    $230.00
    All 3 sizes

1 Item

Added to your cart

View Cart Checkout

    Loading...